We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

SEC Filings

Form 20-F/A
AC IMMUNE SA filed this Form 20-F/A on 04/19/2019
Document Outline
Entire Document (566.7 KB)
Subdocument 1 - 20-F/A - FORM 20-F/A
Page 1 - FORM 20-F/A
Page 2 - Explanatory Note
Page 3 - ITEM 19. Exhibits
Page 4 - Signatures
Subdocument 2 - EX-4.14 - EXHIBIT 4.14
Page 1 - Exhibit 4.14
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - SCHEDULES
Page 5 - Agreement ) is made and entered into effective as of December 11, 2018 (the Execution Date ) by and
Page 6 - 1.4. Additional Indication Triggering Event means [*****].
Page 7 - 1.12. Calendar Year means each successive period of twelve (12) calendar months commencing on Januar
Page 8 - 1.14. CHF means Swiss Francs.
Page 9 - 1.23. Convertible Note Agreement means that certain Convertible Note Agreement dated as of the date
Page 10 - 1.32. European Union or EU means the economic, scientific and political organization of member state
Page 11 - 1.46. Generic Product means, with respect to a Licensed Product, any pharmaceutical product that (i)
Page 12 - 1.51. GxP means compliance with all relevant Regulatory Authority requirements or guidance for Good
Page 13 - 1.60. Insolvency Event means an event in which either Party (i) files for protection under bankruptc
Page 14 - 1.71. Lilly Grantback Patent Rights means, as used in connection with any grant back license provide
Page 15 - 1.79. Person means an individual, sole proprietorship, partnership, limited partnership, limited lia
Page 16 - 1.85. Product Trademarks means the Trademark(s) used or to be used by Lilly or its Sublicensees for
Page 17 - 1.91. Royalty Term means, with respect to each Licensed Product and each country in the Territory, [
Page 18 - 1.104. Unilateral Indication means an Eligible Indication for which ACI exercises the Unilateral Cli
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - 2.1. Grants to Lilly. Subject to the terms and conditions of this Agreement, effective as of the Eff
Page 23 - 2.2.2. a non-exclusive Right of Reference, as that term is defined in 21 C.F.R. 314.3(b) (or any App
Page 24 - 2.4. Retention of Rights.
Page 25 - 2.5.3. Without limitation of the foregoing, ACI shall promptly disclose to Lilly any Improvements wi
Page 26 - 2.7.2. Change of Control of ACI. [*****].
Page 27 - Lilly Pre-Clinical Activities means the activities set forth on Schedule 3.1.2(ii). Lilly may, in it
Page 28 - Diligence Products ).
Page 29 - 3.2. Unilateral Clinical Development Option.
Page 30 - 3.2.4. For the avoidance of doubt, if the exercise of the Unilateral Clinical Development Option is
Page 31 - 3.2.6. Costs of Unilateral Activities; External Development Costs. Unless and until there is a Unila
Page 32 - Assigned Regulatory Documentation and Assigned Regulatory Approvals ), [*****]. ACI shall duly execu
Page 33 - 3.3.4. Global Safety Database. At the time Lilly submits a Drug Approval Application, Lilly shall es
Page 34 - 4.4. Compliance with Applicable Law. Lilly shall and shall cause its Sublicensees to, comply with al
Page 35 - 5.2. General Provisions Applicable to the JSC.
Page 36 - 5.2.3. Decision-Making. Except for matters outside the jurisdiction and authority of the JSC (includ
Page 37 - 5.2.6. Subcommittees.
Page 38 - 6.1. Supply of Licensed Products.
Page 39 - 6.2. Visits to Facilities. Prior to ACI s completion of the transition of Manufacturing activities f
Page 40 - N/A
Page 41 - 7.2.2. Commercial Milestones. In partial consideration of the license rights granted by ACI to Lilly
Page 42 - 7.3. Royalties.
Page 43 - 7.3.3. Reductions. Notwithstanding the foregoing, in the event that:
Page 44 - 7.6.2. ACI shall promptly inform Lilly upon ACI determining that it is likely to overspend or unders
Page 45 - 7.6.4. Additional Indication Clinical Funding Option. In the event that the JSC determines to pursue
Page 46 - 7.8. Taxes.
Page 47 - 7.9. Interest on Late Payments. If any payment due to either Party under this Agreement is not paid
Page 48 - 7.11.3. Confidentiality. The receiving Party shall treat all information subject to review under thi
Page 49 - 8.1.3. Lilly and ACI Program IP. As between the Parties, [*****] shall solely and exclusively own al
Page 50 - 8.1.6. Assignment Obligation. Each Party shall cause all Persons who perform Development activities,
Page 51 - 8.2.2. Patent Prosecution and Maintenance of Lilly Patents. As between the Parties, Lilly shall have
Page 52 - 8.2.5. Patent Listings. The Parties shall, through the Patent Subcommittee, cooperate in good faith
Page 53 - 8.3.3. Enforcement of Lilly Patents. As between the Parties, Lilly shall have the sole right, but no
Page 54 - 8.5. Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other
Page 55 - 8.6. Third Party Rights. If in the reasonable opinion of Lilly, the Exploitation of a Licensed Compo
Page 56 - 8.8. ACI s Corporate Names.
Page 57 - 9.1.1. is or hereafter becomes part of the public domain by public use, publication, general knowled
Page 58 - 9.2.1. made in response to a valid order of a court of competent jurisdiction or Governmental Author
Page 59 - 9.7. Publications. The Parties recognize the desirability of publishing and publicly disclosing the
Page 60 - 10.1. Mutual Representations and Warranties. ACI and Lilly each represents and warrants to the other
Page 61 - 10.1.6. Neither it nor any of its Affiliates, nor any of its or their respective officers, employees
Page 62 - 10.2.6. Neither ACI nor any of its Affiliates has previously entered into any agreement, whether wri
Page 63 - 10.2.14. The inventions claimed or covered by the Existing Patents (i) were not conceived, discovere
Page 64 - Government Official means: (i) any officer or employee of: (a) a government, or any department or ag
Page 65 - 11.2. Indemnification of Lilly. ACI shall indemnify Lilly, its Affiliates, and its and their respect
Page 66 - 11.3.3. Right to Participate in Defense. Any Indemnified Party shall be entitled to participate in,
Page 67 - 11.3.6. Expenses. Except as provided above, the costs and expenses, including fees and disbursements
Page 68 - 12.2.1. Material Breach. In the event that either Party (the Breaching Party ) shall be in material
Page 69 - 12.3. Rights in Bankruptcy. In the event of any Insolvency Event of ACI, Lilly, in addition to the r
Page 70 - N/A
Page 71 - N/A
Page 72 - Termination Royalty Product ) in any country, until the expiration of the last-to-expire Tau Patent
Page 73 - 13.1. Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deem
Page 74 - 13.3.2. The rights to Information, materials and intellectual property: (i) controlled by a Third Pa
Page 75 - 13.4. Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceab
Page 76 - 13.6. Governing Law. This Agreement shall be governed by and construed in accordance with the laws o
Page 77 - 13.8. Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, set
Page 78 - 13.11. Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived a
Page 79 - 13.15. HSR Act Compliance.
Page 80 - 13.18. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which s
Page 81 - N/A
Page 82 - Schedule 1.65
Page 83 - Schedule 1.93
Page 84 - Schedule 3.1.2(i)
Page 85 - Schedule 3.1.2(ii)
Page 86 - Schedule 9.6
Page 87 - AC Immune and Lilly Announce License and Collaboration Agreement
Page 88 - About AC Immune s Tau Morphomers
Page 89 - Lilly Forward-Looking Statement
Page 90 - Lilly Investor Relations
Page 91 - Lilly Press Release
Page 92 - Lilly and AC Immune Announce License and Collaboration Agreement
Page 93 - About AC Immune s Tau Morphomers
Page 94 - About Eli Lilly and Company
Page 95 - N/A
Page 96 - Schedule 10.2.2
Subdocument 3 - EX-12.1 - EXHIBIT 12.1
Page 1 - N/A
Subdocument 4 - EX-12.2 - EXHIBIT 12.2
Page 1 - N/A